Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Severe combined immunodeficiency (SCID) T-B+ due to JAK3 deficiency is a form of SCID characterized by severe and recurrent infections, associated with diarrhea and failure to thrive.
Features include always present findings: Recurrent lower respiratory tract infections, Abnormal B cell physiology, Pneumonia, and Absent peripheral lymph nodes in presence of infection and others; and very common findings: Decreased total T cell count, Impaired lymphocyte transformation with phytohemagglutinin, Absent cellular immunity, and Decreased mitogen-induced T-cell proliferation. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 7 | Recurrent lower respiratory tract infections, Severe combined immunodeficiency, Recurrent upper respiratory tract infections |
Lungs and breathing | 5 | Recurrent lower respiratory tract infections, Pneumonia, Recurrent upper respiratory tract infections |
Digestive system | 4 | Intestinal obstruction, Chronic diarrhea, Recurrent infection of the gastrointestinal tract |
Growth and development | 2 | Failure to thrive, Failure to thrive in infancy |
Ears | 2 | Recurrent otitis media, Acute otitis media |
Skin | 2 | Hyperpigmentation of the skin, Skin rash |
Brain and nerves | 1 | Meningitis |
Head and neck | 1 | Abnormal facial shape |
Age of onset: infancy.
JAK3 encodes Janus kinase 3 (1,124 aa). Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Highest expression in Whole Blood (139.2 TPM) and Spleen (108.5 TPM).
T-B+ severe combined immunodeficiency due to JAK3 deficiency is caused by mutations in the JAK3 gene on chromosome 19.
JAK3 is classified as a druggable target (Clinically Actionable, Druggable Genome, Enzyme, Kinase, and Tyrosine Kinase categories) with score 3.1.
Genetic testing for JAK3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 9 always present features, 4 very common features, 6 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for T-B+ severe combined immunodeficiency due to JAK3 deficiency.
3 publications have been identified in PubMed for T-B+ severe combined immunodeficiency due to JAK3 deficiency. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Jeong PS (2026). [PMID: 40280544](https://pubmed.ncbi.nlm.nih.gov/40280544/). *Journal of advanced research*. [Basic Science / Preclinical]
Consonni F (2026). [PMID: 41341763](https://pubmed.ncbi.nlm.nih.gov/41341763/). *The journal of allergy and clinical immunology. Global*. [Review / Meta-Analysis]
Sbruzzi RC (2024). [PMID: 39611146](https://pubmed.ncbi.nlm.nih.gov/39611146/). *Frontiers in immunology*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 8:51 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about T-B+ severe combined immunodeficiency due to JAK3 deficiency